SEC Comment Letter 0000000000-22-013776 to TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
TEVA PHARMACEUTICAL INDUSTRIES LTD
Date: Dec. 21, 2022 · CIK: 0000818686 · Accession: 0000000000-22-013776
AI Filing Summary & Sentiment
File numbers found in text: 001-16174
Letter
United States securities and exchange commission logo December 21, 2022 Eli Kalif Executive Vice President, Chief Financial Officer Teva Pharmaceutical Industries Limited 124 Dvora HaNevi’a Street Tel Aviv, Israel 6944020 Re:Teva Pharmaceutical Industries Limited Form 10-K for the Fiscal Year Ended December 31, 2021 Filed February 9, 2022 File No. 001-16174 Dear Eli Kalif: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
December 21, 2022
Eli Kalif
Executive Vice President, Chief Financial Officer
Teva Pharmaceutical Industries Limited
124 Dvora HaNevi’a Street
Tel Aviv, Israel 6944020
Re:Teva Pharmaceutical Industries Limited
Form 10-K for the Fiscal Year Ended December 31, 2021
Filed February 9, 2022
File No. 001-16174
Dear Eli Kalif:
We have completed our review of your filings. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences